"Timing was right for sale of Synthes" video
Michel Orsinger, head of the orthopedics business of Johnson & Johnson (DePuy Synthes), talks with FuW on the state of integration of Synthes and the culture of the U.S. parent company.
The world's largest healthcare group Johnson & Johnson (J & J) is struggling with the integration of almost a year ago for $ 19.7 billionacquired Swiss-American orthopedic specialist Synthes. "We still have less than half of the necessary work done," says Michel Orsinger, head of the newly created business unit DePuy Synthes, frankly. In an interview with "Finanz und Wirtschaft" he also acknowledges that DePuy Synthes lost in spinal implants business customers as well as employees in research and development. But Orsinger, who previously led the business as Chief Executive Officer of Synthes wants to look forward. He is convinced that Synthes is due to the merging better positioned with the orthopedic activities of J & J to cope with the increasing cost of healthcare.
Mr. Orsinger, the 19.7-billion - $. Purchase of Synthes was the largest ever acquisition in the nearly 130-year history of Johnson & Johnson. How are you progressing w...
